Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02043665
Title Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Viralytics

urinary bladder cancer

lung non-small cell carcinoma


prostate cancer


Coxsackievirus A21

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
John Wayne Cancer Institute Santa Monica California 90404 United States Details
University of Miami Coral Gables Florida 33146 United States Details
Advocate Health Niles Illinois 60714 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
UT Southwestern Dallas Texas 75390 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
Tasman Oncology Research Southport Queensland 4216 Australia Details
Monash Health Clayton Victoria 3168 Australia Details
St Vincent's Hospital, Melbourne Fitzroy Victoria 3065 Australia Details
Barwon Health Geelong Victoria 3220 Australia Details
Epworth HealthCare Richmond Victoria 3121 Australia Details
St John of God Healthcare Subiaco Western Australia 6008 Australia Details
Royal Marsden NHS Foundation Trust Chelsea SW3 6JJ United Kingdom Details
Royal Surrey County Hospital Guildford GU2 7XX United Kingdom Details
St. James University Hospital Leeds LS9 7TF United Kingdom Details
*Shaded cells indicate that there was no data available from for the field